US Oncologist Email List: 27475 Cancer Experts Ready for B2B Outreach

Oncology is one of those markets where the total addressable market looks simple on a slide and complicated the moment an SDR opens a spreadsheet. You are not just targeting doctors. You are targeting medical oncologists, hematologist-oncologists, radiation oncologists, surgical oncologists, gynecologic oncologists, pediatric oncologists, oncology pharmacists, cancer program directors, clinical research investigators, practice administrators, and sometimes nurse navigators or infusion center leaders depending on the product.

That means one generic list of physicians is usually too blunt. A radiation oncology clinic evaluating treatment planning software behaves differently from a community hematology-oncology group evaluating patient engagement tools. A principal investigator at an academic cancer center will care about study start-up timelines and protocol feasibility. A private practice owner may care more about reimbursement, staffing, prior authorization, and whether your platform creates yet another login.

This is why manual research gets expensive fast. A reasonably careful researcher may validate 20 to 40 usable contacts per hour if they are checking name, specialty, location, organization, role, email pattern, and source confidence. For 27,475 oncology contacts, that is not a task. That is a lifestyle choice. Even at 50 contacts per hour, you are looking at roughly 550 hours before QA, enrichment, deduplication, bounce testing, segmentation, and CRM formatting. The cheap list becomes very expensive once humans start fixing it.

The number 27,475 matters, but only if it maps to a real market structure. In oncology, a large national list should ideally include contacts across academic medical centers, NCI-designated cancer centers, integrated delivery networks, community oncology groups, specialty practices, research hospitals, and regional cancer programs. If it over-indexes on a few public hospital directories and ignores community practices, it will look big but perform small.

The US cancer care market is heavily metro-driven, but not exclusively coastal. New York, Los Angeles, Houston, Chicago, Boston, Philadelphia, Dallas-Fort Worth, Atlanta, Miami, Seattle, San Francisco, San Diego, Phoenix, Denver, Minneapolis, Nashville, Cleveland, and St. Louis all show strong oncology concentration for different reasons. Some cities have major research hubs. Others have large aging populations, expanding health systems, strong private practice networks, or big regional referral patterns.

Houston is an obvious oncology gravity center because of MD Anderson and the broader Texas Medical Center ecosystem. Boston has the academic density: Dana-Farber, Mass General Brigham, Beth Israel, biotech adjacency, and a huge research labor market. New York and Los Angeles are sheer population plus institutional depth. Chicago, Philadelphia, and Cleveland bring legacy academic systems and regional referral patterns. Atlanta, Dallas, Phoenix, and Miami are interesting because they combine population growth, private practice networks, and expanding specialty care demand.

For outreach, this matters because the same campaign should not hit every city the same way. An academic investigator in Boston may respond to data, publications, trial infrastructure, or research collaboration. A community oncologist in Phoenix may care about patient throughput, payer friction, infusion operations, and staff time. Same specialty. Different daily pain.

In a deep-dive market build, I would usually split US oncology contacts into three practical city categories.

• Academic and research hubs: Boston, Houston, New York, Philadelphia, San Francisco, Seattle, Durham, Baltimore, Los Angeles, and Chicago. These markets are strong for clinical trial technology, real-world evidence platforms, molecular diagnostics, AI research tooling, lab partnerships, CME, and enterprise healthcare solutions. Messaging should reference evidence, peer validation, and integration burden. These buyers can smell vague claims from across the tumor board room.
• Large community oncology markets: Dallas-Fort Worth, Atlanta, Phoenix, Tampa, Orlando, Miami, Charlotte, Nashville, Las Vegas, Denver, and Columbus. These markets often respond better to operational ROI: fewer admin hours, faster patient identification, reimbursement support, lower no-show rates, smoother referrals, better care coordination. If your email sounds like a journal abstract, you may lose them.
• Regional referral centers and mid-sized metros: Cleveland, St. Louis, Pittsburgh, Indianapolis, Kansas City, Minneapolis, Salt Lake City, San Antonio, Jacksonville, and Milwaukee. These cities can be underrated. They often contain strong systems serving wide geographic areas. Competition in inboxes may be less brutal than Boston or New York, and a well-targeted message can stand out if it speaks to regional care delivery.

The spendthrift move is not to blast all 27,475 contacts on day one. That is how teams turn a valuable dataset into a deliverability bonfire. Start with city-specialty-product fit. If you sell oncology clinical trial recruitment support, begin with academic hubs and research-heavy systems. If you sell prior authorization automation, community oncology groups and larger regional practices may be a better first pass. If you sell diagnostics, segment by specialty and disease area where possible: hematology-oncology versus solid tumor focus, breast oncology, GU oncology, GI oncology, or gynecologic oncology.

Let us use rough, sober numbers. Suppose your healthcare SaaS site gets 10,000 monthly visitors from content, conference traffic, paid search, partner referrals, and organic pages. With B2B website visitor-to-lead conversion typically around 1.5-4%, you might capture 150 to 400 leads per month. If your niche is strong and pages are high-intent, maybe you hit 5-7%, or 500 to 700 leads. Nice. But how many are oncology decision-makers? How many are students, patients, vendors, job seekers, or competitors reading your blog? Traffic is not pipeline until it is qualified.

Then lead-to-opportunity conversion varies widely. Inbound B2B leads often convert at 5-15% overall after qualification and sales follow-up. High-intent demo requests may convert at 20-40%, while ebook or webinar leads may be below 5-10%, based on CRM benchmark analyses, SaaS funnel studies, and B2B marketing operations reports. This is why content-only demand gen can feel productive and still leave sales complaining. The spreadsheet is full, but the pipeline is thin.

Outbound has its own bad math if handled lazily. Cold outbound email reply rates are commonly 1-5%. Well-targeted campaigns may see 6-10%, while positive reply rates often sit closer to 0.5-3%, based on sales engagement platform benchmarks and outbound prospecting studies. So if you email 5,000 oncologists with a generic pitch, you may get replies, but not necessarily good ones. If you email 500 carefully segmented oncology contacts with a specific offer tied to their setting, city, and role, the volume is smaller but the learning is cleaner. That is usually where ROI improves.

The point is not that outbound beats inbound. The point is that verified lead data lets you stop waiting for every buyer to self-identify through a form. Oncology buyers are not browsing your pricing page for fun between consults. Sometimes the right move is to reach them with a concise, relevant note and give them an easy way to say yes, no, or talk to someone else on the team.

A list with 27,475 cancer experts is only useful if it has enough structure to support intelligent outreach. At minimum, I would want name, email, specialty, organization, city, state, country, and ideally job title or role. Better lists also include practice type, hospital affiliation, domain, phone, LinkedIn URL, NPI or public identifier where applicable, source URL, and last verified date.

Email verification matters, but it is not the entire game. A deliverable inbox does not mean a relevant buyer. A valid address for a retired physician is not useful. A catch-all domain may pass technical checks and still bounce later. Hospital systems also change email patterns after mergers, branding updates, and domain migrations. This happens constantly in healthcare. If your vendor cannot explain how contacts are collected, cleaned, and refreshed, assume you will be doing cleanup yourself.

Segmentation is the difference between outreach and noise. A medical device company selling radiation oncology positioning equipment should not send the same copy to hematologist-oncologists. A real-world evidence company should not treat a private practice clinician and an academic research director as identical. A patient engagement platform may want administrators, care coordinators, and practice leaders as much as physicians. The best list is not the biggest one. It is the one that lets you suppress the wrong people quickly.

This is where a data provider like GeoLayer.io can be useful. I would not frame it as magic. It is more practical than that. It gives teams a way to source and structure geography-based, industry-specific B2B contacts without making SDRs live inside search results. For oncology, the value is in reducing research drag and letting the team spend time on message testing, compliance review, routing, and follow-up.

Outreach to oncologists is usually B2B communication, not patient marketing, and an email list of professional contacts is not the same thing as protected health information. Still, healthcare is a trust-sensitive market. If you act sloppy, people notice.

In the US, teams should pay attention to CAN-SPAM requirements: accurate header information, non-deceptive subject lines, a clear identification of the sender, a physical mailing address, and a working opt-out mechanism that is honored promptly. If you are contacting people in states with stricter privacy expectations or dealing with contacts who may be in global systems, legal review becomes even more important. If your campaign touches patient referrals, trial recruitment, or clinical data workflows, get counsel involved before creative SDR improvisation turns into an incident.

Also, do not imply endorsement, partnership, or clinical superiority without evidence. Oncologists are trained to evaluate claims. If your email says your AI tool revolutionizes cancer care and saves doctors hours every day, prepare for deletion or worse. A better email might say, we are helping community oncology teams identify eligible patients for open studies faster, and I am trying to understand whether your group handles trial matching centrally or by physician referral. Boring? Maybe. More believable? Definitely.

Deliverability compliance matters too. Use separate outbound domains, warm them properly, throttle volume, authenticate with SPF, DKIM, and DMARC, and suppress unsubscribes globally. Do not dump 27,475 contacts into a sequence from a fresh domain and call it growth. That is not growth. That is arson with a dashboard.

Here is the segmentation model I would use before sending a single email.

• By specialty: medical oncology, hematology-oncology, radiation oncology, surgical oncology, pediatric oncology, gynecologic oncology, and subspecialty focus where available. This prevents irrelevant offers from reaching the wrong clinician.
• By organization type: academic cancer center, hospital-based program, community oncology practice, multispecialty group, integrated delivery network, research institute, or private clinic. This affects buying process and message tone.
• By geography: national, regional, state, metro, and city clusters. City-based outreach helps with event follow-up, territory assignment, field sales routing, and regional proof points.
• By buyer role: practicing clinician, department chair, medical director, clinical research leader, administrator, operations lead, or executive. A physician may influence adoption, while an administrator may own workflow and budget.
• By likely use case: clinical trials, diagnostics, devices, workflow automation, patient engagement, data analytics, referral management, CME, or pharma services. This is where copy gets sharper.

Once segments exist, run small tests. Try 200 to 500 contacts per segment, not 10,000. Measure bounce rate, open rate if your tools still support reliable tracking, reply rate, positive reply rate, meeting rate, and disqualification reasons. The disqualification reasons are underrated. If ten oncologists reply saying the practice administrator handles this, congratulations, your next list pull should include administrators in those same organizations.

Sales teams often ask for more leads before they have learned from the leads they already touched. That is backwards. Use the first 1,000 contacts to learn which specialty, city, and offer pairing earns real engagement. Then scale. Efficient, low waste, not glamorous. The best revenue operations often looks like good plumbing.

The incumbent approach is familiar: buy a broad healthcare database, export a giant CSV, discover half the specialties are too vague, assign SDRs to clean it, then quietly rebuild the list from scratch through Google, LinkedIn, and hospital websites. Everyone pretends this is normal because the CRM eventually contains rows. Rows are comforting. They are not the same as market coverage.

GeoLayer.io is better positioned for teams that care about geographic and vertical specificity. If your campaign depends on reaching oncologists in specific US cities or states, a geography-aware sourcing workflow is more efficient than wrestling with a generic database filter called healthcare provider and hoping it means what you think it means.

The caveat: no provider should be treated as the only source of truth. For serious oncology selling, I would still cross-check high-value accounts, enrich strategic targets, and let sales add context from calls, conferences, referrals, and account research. But using a verified oncologist list as the starting layer can save a painful amount of time.